Recombinant Human GLP-1 protein (Tagged)
Be the first to review this product! Submit a review
|
(0 Publication)
Recombinant Human GLP-1 protein (Tagged) is a Human Fragment protein, in the 53 to 89 aa range, expressed in Escherichia coli, with >85%, suitable for SDS-PAGE.
View Alternative Names
Pro-glucagon, GCG
- SDS-PAGE
Supplier Data
SDS-PAGE - Recombinant Human GLP-1 protein (Tagged) (AB235719)
(Tris-glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel of ab235719.
Reactivity data
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
GLP-1 influences several physiological functions by acting on its receptor GLP-1R a G-protein coupled receptor. It is not part of a complex but exerts its effects through binding to this receptor. Activation of GLP-1R promotes insulin secretion suppresses glucagon release slows gastric emptying and promotes satiety. This makes GLP-1 an important regulator in energy homeostasis and nutrient absorption. Its effects on appetite and food intake are of particular interest in obesity research.
Pathways
GLP-1 is an essential component of the incretin pathway which regulates insulin secretion in response to food intake. The interaction between GLP-1 and the GLP-1 receptor activates the adenylate cyclase pathway leading to increased cAMP and PKA signaling in pancreatic beta-cells. This chain of events enhances the insulin-secreting ability of these cells. Furthermore GLP-1 has connections with proteins such as insulin and glucagon through its regulatory functions in glucose metabolism.
Specifications
Form
Liquid
General info
Function
Glucagon. Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. Binds to and activates the glucagon receptor GCGR, which couples to the G(s) G protein and elevates intracellular cAMP, triggering downstream metabolic responses (PubMed : 32193322).. Glucagon-like peptide 1. Potent stimulator of glucose-dependent insulin release (PubMed : 22037645, PubMed : 40446798). Also stimulates insulin release in response to IL6 (PubMed : 22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels (PubMed : 10605628, PubMed : 14719035, PubMed : 12554744). May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin (PubMed : 10605628, PubMed : 14719035, PubMed : 12554744). Has growth-promoting activities on intestinal epithelium (PubMed : 10605628, PubMed : 14719035, PubMed : 12554744). May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion (PubMed : 10605628, PubMed : 14719035, PubMed : 12554744). Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation (PubMed : 10605628, PubMed : 14719035, PubMed : 12554744). Inhibits beta cell apoptosis (PubMed : 10605628, PubMed : 14719035, PubMed : 12554744).. Glucagon-like peptide 2. Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.. Oxyntomodulin. Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.. Glicentin. May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.
Sequence similarities
Belongs to the glucagon family.
Post-translational modifications
Proglucagon is post-translationally processed in a tissue-specific manner in pancreatic A cells and intestinal L cells. In pancreatic A cells, the major bioactive hormone is glucagon cleaved by PCSK2/PC2. In the intestinal L cells PCSK1/PC1 liberates GLP-1, GLP-2, glicentin and oxyntomodulin. GLP-1 is further N-terminally truncated by post-translational processing in the intestinal L cells resulting in GLP-1(7-37) GLP-1-(7-36)amide. The C-terminal amidation is neither important for the metabolism of GLP-1 nor for its effects on the endocrine pancreas.
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com